Beleodaq OverviewBelinostat (trade name Beleodaq, previously known as PXD101) is a histone deacetylase inhibitor drug developed by TopoTarget for the treatment of hematological malignancies and solid tumors. It was approved in July 2014 by the US FDA to treat peripheral T-cell lymphoma. In 2007 preliminary results were released from the Phase II clinical trial of intravenous belinostat in combination with carboplatin and paclitaxel for relapsed ovarian cancer.[4&a...
Read more Beleodaq Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Belinostat
Recent Beleodaq Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 500mg
- Powder: 500mg/vial
NDC Database Records for Beleodaq: (2 results)Sorted by National Drug Code
- 68152-108 Beleodaq 500 mg/10ml Intravenous Injection, Powder, Lyophilized, for Solution by Spectrum Pharmaceuticals, Inc.
- 72893-002 Beleodaq 500 mg/10ml Intravenous Injection, Powder, Lyophilized, for Solution by Acrotech Biopharma LLC